AIMS/HYPOTHESIS: Diabetes mellitus is a strong risk factor for the development of heart failure, and left ventricular (LV) hypertrophy has been detected in a significant proportion of diabetic patients. Because several studies have suggested that the Na(+)/H(+) exchanger (NHE1) plays a part in the molecular mechanisms involved in cardiac hypertrophy, we investigated its activity and its role in LV myocytes from the Goto-Kakizaki (GK) rat model of type 2 diabetes. MATERIALS AND METHODS: Fluorometric measurements were used to assess sarcolemmal NHE1 activity in isolated myocytes. NHE1 levels and the possible molecular pathways driving and/or related to NHE1 activity were investigated in relation to the diabetic LV phenotype. RESULTS: Enhanced NHE1 activity was associated with LV myocyte hypertrophy. This occurred in the absence of any change in NHE1 protein levels; however, activation of several molecular pathways related to NHE1 activity was demonstrated. Thus, phosphorylation of the extracellular signal-regulated protein kinase (Erk), of the protein kinase Akt (also known as protein kinase B) and of the Ca(2+)/calmodulin-dependent kinase II was increased in GK LV myocytes. Intracellular Ca(2+) levels were also increased. Chronic treatment (10-12 weeks) with the NHE1 inhibitor cariporide normalised NHE1 activity, decreased [Formula: see text] levels and reduced LV myocyte hypertrophy. Moreover, among the various activated pathways, cariporide treatment markedly reduced Akt activity only. CONCLUSIONS/ INTERPRETATION: These findings indicate that activation of the Akt pathway represents a likely mechanism mediating the hypertrophic effect of increased NHE1 activity in the GK model of type 2 diabetes.
AIMS/HYPOTHESIS: Diabetes mellitus is a strong risk factor for the development of heart failure, and left ventricular (LV) hypertrophy has been detected in a significant proportion of diabeticpatients. Because several studies have suggested that the Na(+)/H(+) exchanger (NHE1) plays a part in the molecular mechanisms involved in cardiac hypertrophy, we investigated its activity and its role in LV myocytes from the Goto-Kakizaki (GK) rat model of type 2 diabetes. MATERIALS AND METHODS: Fluorometric measurements were used to assess sarcolemmal NHE1 activity in isolated myocytes. NHE1 levels and the possible molecular pathways driving and/or related to NHE1 activity were investigated in relation to the diabetic LV phenotype. RESULTS: Enhanced NHE1 activity was associated with LV myocyte hypertrophy. This occurred in the absence of any change in NHE1 protein levels; however, activation of several molecular pathways related to NHE1 activity was demonstrated. Thus, phosphorylation of the extracellular signal-regulated protein kinase (Erk), of the protein kinase Akt (also known as protein kinase B) and of the Ca(2+)/calmodulin-dependent kinase II was increased in GK LV myocytes. Intracellular Ca(2+) levels were also increased. Chronic treatment (10-12 weeks) with the NHE1 inhibitor cariporide normalised NHE1 activity, decreased [Formula: see text] levels and reduced LV myocyte hypertrophy. Moreover, among the various activated pathways, cariporide treatment markedly reduced Akt activity only. CONCLUSIONS/ INTERPRETATION: These findings indicate that activation of the Akt pathway represents a likely mechanism mediating the hypertrophic effect of increased NHE1 activity in the GK model of type 2 diabetes.
Authors: Christophe Depre; Makoto Hase; Vinciane Gaussin; Anna Zajac; Li Wang; Luc Hittinger; Bijan Ghaleh; Xianzhong Yu; Raymond K Kudej; Thomas Wagner; Junichi Sadoshima; Stephen F Vatner Journal: Circ Res Date: 2002-11-29 Impact factor: 17.367
Authors: P Richard; R Isnard; L Carrier; O Dubourg; Y Donatien; B Mathieu; G Bonne; F Gary; P Charron; M Hagege; M Komajda; K Schwartz; B Hainque Journal: J Med Genet Date: 1999-07 Impact factor: 6.318
Authors: K Jandeleit-Dahm; K M Hannan; C A Farrelly; T J Allen; J R Rumble; R E Gilbert; M E Cooper; P J Little Journal: Circ Res Date: 2000-12-08 Impact factor: 17.367
Authors: Lina Al Kury; Vadym Sydorenko; Manal M A Smail; Muhammad Anwar Qureshi; Anatoliy Shmygol; Murat Oz; Jaipaul Singh; Frank Christopher Howarth Journal: Mol Cell Biochem Date: 2018-01-09 Impact factor: 3.396
Authors: Abdullah Kaplan; Emna Abidi; Ahmed El-Yazbi; Ali Eid; George W Booz; Fouad A Zouein Journal: Heart Fail Rev Date: 2018-05 Impact factor: 4.214
Authors: Oscar H Cingolani; Néstor G Pérez; Irene L Ennis; María C Alvarez; Susana M Mosca; Guillermo R Schinella; Eduardo M Escudero; Gloria Cónsole; Horacio E Cingolani Journal: Pflugers Arch Date: 2011-08-26 Impact factor: 3.657
Authors: Sergey Lupachyk; Pierre Watcho; Hanna Shevalye; Igor Vareniuk; Alexander Obrosov; Irina G Obrosova; Mark A Yorek Journal: Am J Physiol Endocrinol Metab Date: 2013-06-04 Impact factor: 4.310
Authors: Vikram Prasad; John N Lorenz; Marian L Miller; Kanimozhi Vairamani; Michelle L Nieman; Yigang Wang; Gary E Shull Journal: J Mol Cell Cardiol Date: 2013-09-29 Impact factor: 5.000